secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001725160-23-000129
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis presents ASCO data: azenosertib+chemo response linked to Cyclin E1
---------------------------------------------------------------------------

- Azenosertib + chemo (paclitaxel, carboplatin, gemcitabine, PLD) shows ORR of 34% across 94 evaluable patients.
- Cyclin E1 IHC+ patients had median PFS 9.86 mo vs 3.25 mo for low (HR 0.37, p=0.0078).
- RP2D set: azenosertib 300 mg QD 5:2 + paclitaxel 80 mg/m2; RP2D with carboplatin 200 mg QD 5:2.
- Phase 3 design proposed comparing azenosertib+chemo vs carboplatin doublet in Cyclin E1+ platinum-sensitive ovarian cancer.
- ZN-d5 (BCL-2) + azenosertib phase 1/2 in AML enrolling; no efficacy data yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000129/0001725160-23-000129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000129/zntl-20230605.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer